Always a pleasure to catch-up with Editorial Board member, Bengt Winblad (Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden), who chatted with us on several topics including the recent resurrection of an investigational human monoclonal antibody targeting beta-amyloid for the treatment of early Alzheimer’s disease (AD).
What is your opinion of the resurrection of aducanumab for AD? (0:05)
Also see linked videos with Bengt Winblad:
Overview of the MOPEAD Project
Emerging therapeutic targets for Alzheimer’s disease
Swedish Geriatric Neurologist Perspective on COVID-19
Speaker disclosure: Bengt Winblad has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.
Share this Video
Related Videos In Alzheimer's Disease & Dementia
Gabriel A de Erausquin, AAIC 2021: The Alzheimer’s Association-led Global SARS-CoV-2 Consortium
touchNEUROLOGY joins Gabriel de Erausquin (UT Health San Antonio, TX, USA) at AAIC 2021 to discuss the Alzheimer’s Association-led Global SARS-CoV-2 Consortium and the links between long-term cognitive dysfunction, acceleration of Alzheimer’s symptoms and COVID-19. Questions Could you tell us a little about the Alzheimer’s Association-led global SARS-CoV-2 consortium? (00:30-02:07) What were the aims and […]
Jeffrey Cummings, AAIC 2021: Aducanumab for the Treatment of Early Alzheimer’s Disease
touchNEUROLOGY joins Jeffrey Cummings (University of Nevada, Las Vegas, NV, USA) at AAIC 2021 to discuss the EMERGE clinical trial findings and what this means for the use of aducanumab on the treatment of patients with Alzheimer’s disease. The abstract entitled “Item-level analysis of clinical measures in patients with early symptomatic Alzheimer’s disease following treatment […]
Marwan Sabbagh: Approval of Aducanumab for Alzheimer’s Disease
It was a great pleasure to meet up with Marwan Sabbagh (Cleveland Clinic Lerner College of Medicine, Las Vegas, NV, USA), to discuss the recent approval of aducanumab for Alzheimer’s Disease. Aducanumab was granted accelerated approval on June 7 2021, by the U.S. Food and Drug Administration (FDA). Questions: Could you give us a brief […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!